Keros gives Han­soh sub­sidiary li­cense for lead drug in $190M+ deal; Vac­citech snaps up new tools in small buy­out 

Mass­a­chu­setts biotech Keros Ther­a­peu­tics now has a deal with Han­soh Healthtech, a Han­soh Phar­ma­ceu­ti­cal Group sub­sidiary, in the form of an ex­clu­sive li­cense.

The deal was an­nounced ear­li­er this week, with Han­soh get­ting the li­cense from Keros to de­vel­op, man­u­fac­ture and com­mer­cial­ize KER-050 with­in Chi­na, Hong Kong and Macau.

KER-050, an en­gi­neered lig­and trap and Keros’ lead drug can­di­date, is in Phase II tri­als for myelodys­plas­tic syn­drome and a bone mar­row can­cer known as myelofi­bro­sis. The drug is de­signed to in­crease the pro­duc­tion of platelets and red blood cells and treat low blood cell counts such as ane­mia, ac­cord­ing to Keros.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER